MAPK1 and breast carcinoma: Although case numbers are small for SMAα low subsets, it appears that ERα-positive breast cancer patients only benefit from tamoxifen treatment when the surrounding CAFs exhibit high ERK phosphorylation as well as high SMAα expression.